Valuation: Pulike Biological Engineering, Inc.

Market Cap 3.49B 515M 451M 416M 384M 729M 49.15B 741M 4.97B 1.95B 24.21B 1.94B 1.89B 83.24B P/E 2026 *
20.4x
P/E 2027 * 15.1x
Enterprise Value 3.49B 515M 451M 416M 384M 729M 49.15B 741M 4.97B 1.95B 24.21B 1.94B 1.89B 83.24B EV / Sales 2026 *
3.18x
EV / Sales 2027 * 2.66x
Free-Float
54.3%
Yield 2026 *
-
Yield 2027 * -
1 day+0.99%
1 week-2.20%
Current month+4.39%
1 month-2.39%
3 months-19.91%
6 months-20.65%
Current year-17.78%
1 week 9.97
Extreme 9.97
10.75
1 month 9.56
Extreme 9.56
10.75
Current year 9.56
Extreme 9.56
14.37
1 year 9.56
Extreme 9.56
15.79
3 years 9.56
Extreme 9.56
25
5 years 9.56
Extreme 9.56
34.9
10 years 9.56
Extreme 9.56
34.9
Manager TitleAgeSince
Chief Executive Officer 53 2020-02-25
Director of Finance/CFO 53 2011-03-22
Corporate Secretary 42 2016-05-03
Director TitleAgeSince
Director/Board Member 61 2023-04-10
Director/Board Member 61 2023-04-10
Director/Board Member 53 2011-03-22
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%-2.20%-26.53%-55.49% 515M
+0.64%+1.02%-52.42%-55.61% 31.68B
+0.81%-0.72%+65.03%+144.53% 12.4B
+0.77%-6.73%-18.89%-1.99% 3.59B
+1.10%-3.46%-7.10%+26.18% 3.07B
0.00%-1.06%+53.40%+26.61% 1.96B
+0.16%+0.50%-28.82%+21.31% 1.67B
-0.96%-3.58%+2.99%+124.74% 1.3B
+1.57%-1.02%-19.74%-13.69% 1.04B
-0.42%+0.28%-8.51%-18.67% 943M
Average +0.47%-2.24%-4.06%+19.79% 5.82B
Weighted average by Cap. +0.64%-0.45%-15.91%+5.04%

Financials

2026 *2027 *
Net sales 1.1B 162M 142M 131M 121M 229M 15.44B 233M 1.56B 613M 7.61B 608M 595M 26.14B 1.32B 194M 170M 156M 145M 274M 18.5B 279M 1.87B 734M 9.11B 728M 712M 31.33B
Net income 172M 25.29M 22.12M 20.41M 18.85M 35.76M 2.41B 36.36M 244M 95.75M 1.19B 94.97M 92.9M 4.09B 238M 35.1M 30.7M 28.32M 26.15M 49.62M 3.35B 50.46M 338M 133M 1.65B 132M 129M 5.67B
Net Debt - -
Logo Pulike Biological Engineering, Inc.
Pulike Biological Engineering Inc is a China-based company primarily engaged in the research, development, production, and sale of veterinary biological products, chemical pharmaceuticals, and traditional Chinese veterinary medicines. The Company’s swine products include porcine circovirus bivalent inactivated vaccine, porcine circovirus type 2 genetically engineered subunit vaccine (Yuankexin) and others. The Company’s poultry products include new branch (Re-9 strain) triple inactivated vaccine, the new branch method (rVP2 protein) quadruple inactivated vaccine and others. The Company’s pet products include triple inactivated feline vaccine, combination of pyroptidine drops (Beichong'en), imidacloprid and moxidectin drops and others. The Company conducts its business in the domestic and overseas markets.
Employees
1,519
Date Price Change Volume
26-07-10 CN¥10.22 +0.99% 2,421,800
26-07-09 CN¥10.12 -1.65% 2,270,800
26-07-08 CN¥10.29 +0.49% 2,214,990
26-07-07 CN¥10.24 -2.94% 2,569,300
26-07-06 CN¥10.55 +0.96% 4,079,112
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.22CNY
Average target price
15.44CNY
Spread / Average Target
+51.08%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 603566 Stock